Health spending continues to stagnate, says OECD

27 June 2013

Health spending has remained flat in the 34 member countries of the Organization for Economic Cooperation and Development (OECD), it said today. After falling sharply in 2010, the economic crisis has continued to have an impact on spending, particularly in European countries hit hardest by the crash, according to the OECD Health Data 2013.

The report says while health spending grew on average by close to 5% year-on-year from 2000 to 2009, this has been followed by a slow growth of around 0.5% in 2010 and 2011. Current expenditure on health grew by 0.7% in both years with preliminary figures for some countries suggesting a continuation of this trend in 2012.

The OECD report says the drop has been primarily driven by a collapse in the growth of government health spending since 2009 – recording close to zero growth in both years on average. Only two OECD countries, Israel and Japan, saw an acceleration in health spending since 2009 compared with the period before.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics